CN112626037B - Construction and application of green fluorescent protein-labeled recombinant iridovirus - Google Patents

Construction and application of green fluorescent protein-labeled recombinant iridovirus Download PDF

Info

Publication number
CN112626037B
CN112626037B CN202110008453.9A CN202110008453A CN112626037B CN 112626037 B CN112626037 B CN 112626037B CN 202110008453 A CN202110008453 A CN 202110008453A CN 112626037 B CN112626037 B CN 112626037B
Authority
CN
China
Prior art keywords
iridovirus
recombinant
green fluorescent
fluorescent protein
egfp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110008453.9A
Other languages
Chinese (zh)
Other versions
CN112626037A (en
Inventor
王帆
赖翠欣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shantou University
Original Assignee
Shantou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shantou University filed Critical Shantou University
Priority to CN202110008453.9A priority Critical patent/CN112626037B/en
Publication of CN112626037A publication Critical patent/CN112626037A/en
Application granted granted Critical
Publication of CN112626037B publication Critical patent/CN112626037B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/00021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/00022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/00051Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides a construction method and application of a green fluorescent protein marked recombinant iridovirus. And inserting eGFP and Flag labels into the C end of the main capsid protein coding gene by adopting a homologous recombination method, and further screening out the green fluorescent protein marked recombinant iridovirus by a cell sorter and a limiting dilution method. For the target virus, it was verified by Western Blot whether eGFP and Flag tags were inserted at preset positions, and the exact positions of eGFP and Flag insertion were further determined by viral genome sequencing. Finally, the structural difference between the green fluorescent protein-labeled recombinant iridovirus and the wild type is observed by using a transmission electron microscope and an atomic force microscope, and the result shows that the structural sizes of the two are basically consistent without obvious difference. The recombinant virus is used as a molecular tool for researching the interaction between the virus and a host, has important value in immunological research, and provides a new tool for further researching the antiviral immunity of fish.

Description

Construction and application of green fluorescent protein-labeled recombinant iridovirus
Technical Field
The present invention relates to the field of biotechnology.
Background
With the rapid development of economy, the living standard of people is gradually improved, and the demands of high-protein aquatic products are also increasing. The expansion of aquaculture scale is increasingly limited by environmental and cultivation techniques, especially large-scale diseases caused by viruses, resulting in huge economic losses.
Iridovirus (SGIV) is a virus with deadly infectious power to economic fishes, and is one of the most important causes of death of cultured animals in many times in recent years, and the research on immune mechanisms has been carried out more. However, to truly understand the pathogenesis of SGIV and the control method, further research into details of the viral infection process is still needed.
Disclosure of Invention
In the recombinant iridovirus of this item, the green fluorescent protein successfully marks part of the main capsid protein of the virus, and the recombinant virus not only can make infected cells appear green under a fluorescent microscope, but also can normally infect and replicate in the body of garrupa, and the green fluorescent signal is detected by flow sorting analysis of the infected blood cells. The successful construction of the virus enables people to observe the whole process of the iridovirus infecting the host in real time, and is an effective tool for exploring the interaction between the iridovirus and the host.
The technical scheme adopted by the invention is as follows:
according to the invention, wild garrupa iridovirus (Singapore Grouper Iridovirus, SGIV) is taken as a transformation object, the C end of ORF72R gene for expressing main capsid protein (Major Capsid Protein, MCP) is taken as an insertion site, plasmid with eGFP and Flag label and ORF72R fusion expression is constructed, the plasmid is transferred into garrupa embryo stem cells by a liposome transfection method, a flow sorter is utilized to screen out target viruses, namely cells with green fluorescent signals, and the target viruses are purified by a limiting dilution method, so that the obtained viruses are named SGIV-72R-eGFP. And then Western Blot and immunoprecipitation are used for analyzing whether eGFP and Flag labels are correctly inserted into preset positions, and a transmission electron microscope is used for observing that the recombinant green fluorescent iridovirus and the wild garrupa iridovirus have similar characteristics in structure and size, and no obvious difference exists between the two.
Compared with the prior art, the green fluorescent protein label has the following advantages and beneficial effects:
recombinant viruses are of great value in immunological research as a molecular tool for studying the interaction of viruses with hosts. At present, the research on mammal recombinant viruses is more, the recombinant viruses related to aquatic viruses are relatively less, and the green fluorescent protein-marked recombinant iridovirus constructed by the invention provides a new tool for further researching fish antiviral immunity.
Drawings
FIG. 1 is a fluorescence microscope image of green fluorescent protein-labeled recombinant iridovirus infecting garrupa embryonic stem cells;
FIG. 2 is a diagram comparing purified green fluorescent protein-labeled recombinant iridovirus with wild-type virus;
FIG. 3 is a Western Blot diagram of green fluorescent protein labeled recombinant iridovirus versus wild-type virus;
FIG. 4 is a graph of immunoprecipitation analysis of wild-type iridovirus and green fluorescent protein-labeled recombinant iridovirus;
FIG. 5 is a transmission electron microscope image of a green fluorescent protein labeled recombinant iridovirus versus wild-type virus;
FIG. 6 is a flow-based sorting analysis of blood cell green fluorescent protein markers infected with recombinant green fluorescent iridovirus.
Detailed Description
The invention will be described in further detail below with reference to the drawings by means of specific embodiments. It will be appreciated by those skilled in the art that the following examples are illustrative of the present invention and should not be construed as limiting the scope of the invention. The specific techniques or conditions are not noted in the examples, and are carried out according to techniques or conditions described in the literature in the art (for example, refer to J. Sam Brookfield et al, ind. Molecular cloning Experimental guidelines, third edition, scientific Press) or according to the product specifications. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1: construction, screening and purification of green fluorescent protein marked recombinant iridovirus
1) The ORF72R gene expressing MCP in SGIV was selected as a target gene to construct a recombinant plasmid, and the C-terminus of MCP was inserted with eGFP and Flag tags.
2) The recombinant virus is obtained by homologous recombination between wild virus and recombinant plasmid, the recombinant plasmid enters into garrupa embryo stem cells in the growth logarithmic phase by a liposome transfection method, and after the wild virus is inoculated for 48 hours, a fluorescence microscope is used for observing whether the recombinant virus is generated.
3) The infected cells are collected, the cells with green fluorescence are screened by a flow cell sorter, the screening process is repeated for a plurality of times, and the obtained infected cells are prepared into virus suspension by an ultrasonic disruption method.
Example 2: screening and purifying of green fluorescent protein marked recombinant iridovirus
1) The virus suspension obtained in example 1 was subjected to gradient dilution and inoculated in 96-well plates, and after 48h, significant cytopathic effect CPE was present. And screening out holes for detecting single green fluorescent CPE by using an inverted fluorescent microscope, namely, single green fluorescent protein labeled recombinant iridovirus clone. FIG. 1 is a microscopic image of green fluorescent protein-labeled recombinant iridovirus infected grouper embryo cells.
2) Green fluorescent protein markers cell suspensions containing large amounts of virus were obtained by cell culture, using garrupa embryonic stem cells in log phase of growth, and recombinant virus with moi=10 was added. After about 3-4 days, the infected cells were detached, suspended in medium, and the cells were collected and washed several times with 0.01M PBS.
3) The cell suspension was sonicated until the solution was clear, and then sucrose density gradient centrifugation was performed, setting sucrose density gradients of 30%, 40%, 50%, 60%. The cell suspension after ultrasonic disruption is paved on the 30% sucrose solution of the uppermost layer, and is centrifuged for 1h at 20000rpm and 4 ℃, and the green fluorescent protein marked recombinant iridovirus particles are suspended in the 50-60% sucrose layer. Taking out the virus suspension of the layer, diluting with a proper amount of 0.01M PBS, centrifuging at 20000rpm and 4 ℃ for 30min, and obtaining a pale yellow precipitate which is the purified green fluorescent protein-marked recombinant iridovirus, re-suspending with a proper amount of TN buffer, and preserving at-80 ℃. FIG. 2 is a comparison of purified green fluorescent protein-labeled recombinant iridovirus and wild-type iridovirus under UV.
Example 3: identification of green fluorescent protein-labeled recombinant iridovirus
1) Western Blot was performed using purified wild-type iridovirus and green fluorescent protein-labeled recombinant iridovirus, with Anti-MCP, anti-eGFP and Anti-Flag as primary antibodies, respectively. The results showed that in wild-type iridovirus the band position of MCP was around 50kDa, whereas the band of recombinant virus MCP was around 75kDa, i.e. the size of MCP after fusion expression with eGFP and Flag tag, and antibodies to eGFP and Flag also detected this band in recombinant virus, indicating correct insertion of eGFP and Flag tag into MCP. FIG. 3 is a Western Blot plot of wild-type iridovirus and green fluorescent protein-labeled recombinant iridovirus.
2) Immunoprecipitation analysis is carried out on the purified wild iridovirus and the green fluorescent protein-labeled recombinant iridovirus, and the Flag tag antibody is utilized for detecting the interaction protein. The results showed that in recombinant iridovirus, a differential band was detected around 75kDa, i.e.MCP-eGFP-Flag, further demonstrating the correct insertion of eGFP and Flag tags into MCP. FIG. 4 is an immunoprecipitation analysis of wild-type iridovirus and green fluorescent protein-labeled recombinant iridovirus.
3) About 10ul of purified green fluorescent protein marked recombinant iridovirus and wild iridovirus suspension is dripped on a copper mesh of a 200-mesh ordinary carbon film, and is left stand for 10min, after the surplus liquid is absorbed, the solution is subjected to negative dyeing by using 2% PFA, and after the solution is dyed for 5min, the surplus liquid is absorbed. Compared with wild iridovirus, the recombinant green fluorescent iridovirus has basically consistent structure and size, and the green fluorescent protein markers have no obvious difference when observed by a transmission electron microscope. FIG. 5 is a transmission electron microscope image of green fluorescent protein-labeled recombinant iridovirus (a) and wild-type iridovirus (b).
Example 4: preliminary application of green fluorescent protein marked recombinant iridovirus
1) Taking grouper seedlings purchased from a farm and temporarily raised for 30 days, setting a control group and an experimental group, injecting 100 mu L of PBS into the control group, injecting 100 mu L of purified recombinant iridovirus SGIV-72R-eGFP into the experimental group, and attacking the grouper seedlings with a virus concentration of 1 multiplied by 10 6.5 pfu/mL, using a 1mL sterile syringe to inject toxin from the abdominal cavity of the fish;
2) After 14d, the fish blood is drawn by pinching the gill of the fish blood with wet cloth and adopting a tail vein blood drawing method, a proper amount of anticoagulant is added into a 1mL needle tube to prevent coagulation, and then the fish blood cells are collected for flow sorting analysis after centrifugation for 5min at 1000 Xg at 4 ℃.
3) The blood cells of the fish were resuspended in 0.01M PBS and passed through the filters of the flow tube before loading and 10,000 cells were collected for analysis. The blood cells infected by the recombinant iridovirus have obvious green fluorescence signals, which indicates that the recombinant iridovirus marked by the green fluorescence protein can be infected and replicated in the body of the grouper, and the green fluorescence signals can be detected by a flow cytometer. FIG. 6 is a flow-based sorting analysis of blood cells infected with green fluorescent protein-labeled recombinant iridovirus.

Claims (2)

1. The construction method of the green fluorescent protein marked recombinant iridovirus is characterized by comprising the following steps:
1) Constructing a recombinant plasmid, and selecting the C end of the ORF72R gene of the garrupa iridovirus as an insertion site of eGFP and Flag tags, wherein the recombinant plasmid contains the ORF72R gene fused with the eGFP and Flag tags;
2) The recombinant virus is obtained by homologous recombination between wild type virus and recombinant plasmid, the recombinant plasmid enters into garrupa embryo stem cells in the growth log phase by a liposome transfection method, and then the garrupa embryo stem cells are inoculated with wild iridovirus;
3) Collecting infected cells, screening out cells with green fluorescence, and extracting intracellular viruses, namely, green fluorescent protein-labeled recombinant iridovirus;
4) And (3) after the screened and purified green fluorescent protein marked recombinant iridovirus is subjected to amplification culture, separating by a sucrose density gradient centrifugation method, wherein the green fluorescent protein marked recombinant iridovirus is suspended in a 50-60% sucrose solution.
2. The method for constructing a green fluorescent protein-labeled recombinant iridovirus according to claim 1, further comprising the step of, after step 4):
5) And (3) identifying the green fluorescent protein-labeled recombinant iridovirus obtained in the step 4) by a western blotting method.
CN202110008453.9A 2021-01-05 2021-01-05 Construction and application of green fluorescent protein-labeled recombinant iridovirus Active CN112626037B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110008453.9A CN112626037B (en) 2021-01-05 2021-01-05 Construction and application of green fluorescent protein-labeled recombinant iridovirus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110008453.9A CN112626037B (en) 2021-01-05 2021-01-05 Construction and application of green fluorescent protein-labeled recombinant iridovirus

Publications (2)

Publication Number Publication Date
CN112626037A CN112626037A (en) 2021-04-09
CN112626037B true CN112626037B (en) 2023-06-06

Family

ID=75290660

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110008453.9A Active CN112626037B (en) 2021-01-05 2021-01-05 Construction and application of green fluorescent protein-labeled recombinant iridovirus

Country Status (1)

Country Link
CN (1) CN112626037B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102242173A (en) * 2011-04-29 2011-11-16 中国科学院南海海洋研究所 Extraction method for envelope protein of grouper iridovirus
WO2012037723A1 (en) * 2010-09-21 2012-03-29 中山大学 Attenuate live vaccine of vsocs gene-deleted megalocytivirus, method to prepare the same and use thereof
WO2012122858A1 (en) * 2011-03-17 2012-09-20 中国科学院上海巴斯德研究所 Method for producing virus-like particle by using drosophila cell and applications thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087331A1 (en) * 2003-05-15 2007-04-19 Cytos Biotechnology Ag Selection of b cells with specificity if interest: method of preparation and use
US20130177582A1 (en) * 2010-04-29 2013-07-11 Riemser Arzneimittel Ag Parapoxvirus expressing the vp60 major capsid protein of the rabbit haemorrhagic disease virus
CN102277361A (en) * 2011-04-29 2011-12-14 中国科学院南海海洋研究所 Method for screening protective antigens of Singapore grouper iridovirus
CN107794291A (en) * 2017-04-10 2018-03-13 中山大学 A kind of drug screening method of anti-Singapore's grouper irido virus
CN108384763B (en) * 2018-03-14 2022-02-11 中山大学 Infectious spleen and kidney necrosis virus ORF074 gene deletion strain and preparation method and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012037723A1 (en) * 2010-09-21 2012-03-29 中山大学 Attenuate live vaccine of vsocs gene-deleted megalocytivirus, method to prepare the same and use thereof
WO2012122858A1 (en) * 2011-03-17 2012-09-20 中国科学院上海巴斯德研究所 Method for producing virus-like particle by using drosophila cell and applications thereof
CN102242173A (en) * 2011-04-29 2011-11-16 中国科学院南海海洋研究所 Extraction method for envelope protein of grouper iridovirus

Also Published As

Publication number Publication date
CN112626037A (en) 2021-04-09

Similar Documents

Publication Publication Date Title
de León et al. Laboratory methods to study African swine fever virus
US9598671B2 (en) Cyprinid herpesvirus II-sensitive brain tissue cell line of Carassius auratus gibelio and establishing method and use thereof
CN109971710A (en) Jian carp brain cell line and its method for building up and application
Au et al. Microinjection of Xenopus laevis oocytes as a system for studying nuclear transport of viruses
CN112941011B (en) Epinephelus lanceolatus head kidney cell line and construction method and application thereof
CN112626037B (en) Construction and application of green fluorescent protein-labeled recombinant iridovirus
CN113980912A (en) Gene knockout cell line capable of replicating IBV virus QX subtype strain and construction method and application thereof
CN104561092A (en) Construction method and applications of genetically engineered vaccine of recombinant PRRS virus capable of expressing classic swine fever virus (CSFV) E2 protein
Wang et al. Establishment and characterization of a new cell line from koi brain (Cyprinus carpio L.)
Lee et al. Superinfection-induced apoptosis and its correlation with the reduction of viral progeny in cells persistently infected with Hz-1 baculovirus
CN107296956A (en) A kind of genetic recombination live vector vaccine
CN114058566B (en) Mandarin skin cell line and application thereof
CN114874974B (en) Epinephelus coioides intestinal cell line ECGI-21 and application thereof
CN113416713A (en) Construction and application of recombinant adenovirus
Gu et al. Establishment of spiroplasma-infected hemocytes as an in vitro laboratory culture model of Chinese mitten crab Eriocheir sinensis
CN104774873B (en) A kind of assembled in vitro GCRV preparation method
CN112980767A (en) Nodevirus-free monoclonal insect cell line and application thereof
US5236840A (en) Method for growing crustacean virus in fish cells
CN110184243A (en) The method and its kit of Antheraea pernyi nuclear polyhedrosis virus genomic DNA linearisation
CN110295137A (en) A kind of crow snakehead kidney cell line and its construction method and application
CN117904032B (en) Sea bass fin line cell line and application thereof
CN117625688B (en) Reverse genetic operating system for B subtype avian metapneumovirus and application thereof
CN107881157B (en) Double-gene knockout strain of oncocyte virus vSOCS/vTK as well as preparation method and application thereof
CN115851574B (en) Beet armyworm cell line
CN117143806B (en) Cell line of garrupa fries, construction method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant